The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
ORGANIZATION
JPMA Suspends Ono’s Membership over Onoact Bribery Case
The Japan Pharmaceutical Manufacturers Association (JPMA) on September 16 suspended the membership of Ono Pharmaceutical after two of its employees were found guilty over bribery charges linked to the company’s anti-arrhythmic drug Onoact (landiolol). The membership suspension is the second…
To read the full story
Related Article
- Maker FTC Issues “Warning” to Ono over Onoact Bribery Case
December 16, 2021
- Hisamitsu Ordered to Suspend Biz over Salonpas OTC Data Tampering
August 13, 2021
- Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
ORGANIZATION
- Pharma FTC Clarifies “Simple Beverages” under New Food Rules
January 14, 2026
- EFPIA Japan Appoints Novartis’ Pullicino as Vice Chair
January 9, 2026
- FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
- Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
- Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…